Charting a New World of Medicines

Vedanta is advancing a pipeline of programs that seek to address serious infectious and immune diseases by using defined consortia of immune-modulating bacteria that restore colonization resistance against gut pathogens and stimulate protective immune responses.

Program Indication Discovery Preclinical Manufacturing Phase 1 Phase 2
VE303 Powered by Carb-X C. difficile
Discovery Phase complete
Preclinical Phase complete
Manufacturing Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
VE202 Janssen Inflammatory Bowel Diseases
Discovery Phase complete
Preclinical Phase complete
Manufacturing Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
VE416 Food Allergy
Discovery Phase complete
Preclinical Phase complete
Manufacturing Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Multi-drug Resistant Organisms and Graft-vs-Host Disease
Discovery Phase complete
Preclinical Phase in progress
Manufacturing Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
VE800 Cancer Immunotherapy
Discovery Phase complete
Preclinical Phase complete
Manufacturing Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started

Our Partners

We aim to collaborate with partners to advance bacterial consortia therapeutics either through direct licensing of our products or our intellectual property.

We also collaborate with clinical and academic institutions to learn from human interventional studies and to further our mechanistic understanding of bacterial consortia therapeutics.

View Partnerships

The Leading Platform for Development of Bacterial Consortia Therapeutics

Our discovery platform enables identification of bacterial consortia with drug-like properties and their manufacture to GMP standards.

How Our Proprietary Discovery Platform Works